GUELPH, ON,
Aug. 24, 2012 /PRNewswire/ - BIOREM
Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its
results for the three-month period ended June 30, 2012. Biorem's complete 2012
second quarter financial statements and MD&A have been filed on
SEDAR (www.sedar.com).
Financial Summary:
|
|
|
|
|
|
Three-months ended
June 30, |
Six-months ended
June 30, |
(in thousands of Canadian dollars, except percent and per
share data) |
2012 |
2011 |
2012 |
2011 |
REVENUE |
$2,873 |
$3,902 |
$6,140 |
$7,634 |
RESULTS FROM OPERATING ACTIVITIES |
$(615) |
$(415) |
$(1,098) |
$(322) |
NET EARNINGS/(LOSS) |
$(680) |
$(496) |
$(1,224) |
$(516) |
BASIC EARNINGS/(LOSS) PER SHARE
DILUTED EARNINGS/(LOSS) PER SHARE |
$(0.05)
$(0.05) |
$(0.04)
$(0.04) |
$(0.09)
$(0.09) |
$(0.04)
$(0.04) |
Revenues for the three months ended June 30, 2012 were $2.8
million compared to $3.3
million recorded the previous quarter, and $3.9 million in the similar period in the prior
year. Six month revenues to June 30
totaled $6.1 million, a $1.5 million decrease from $7.6 million in revenues for the six months ended
June 30, 2011.
Gross profit for the quarter was $490,000 representing 17% of revenues, a
$110,000 improvement over the
$380,000 of gross profit and 11.7% of
revenues in realized in Q1 2012.
The Company recorded a net loss for the quarter
of $680,000 representing a loss of
$0.05 per share. The net loss for the
six months ended June 30, 2012 was
$1,224,000, a loss per share of
$0.09.
The Company's backlog of orders at June 30, 2012 stood at $13.6 million, a $1.6
million improvement over the order back log at June 30, 2011. However, as at August 21, 2012 this backlog had grown to
$17.5 million.
As previously announced, during Q2 2012 the
Company issued convertible secured debentures for gross proceeds of
$659,000.
Subsequent to June 30,
2012 the Company improved its working capital position by
issuing additional convertible secured debentures for gross
proceeds of $1.1 million and received
$500,000 in additional debt financing
through an amending agreement with the existing lender of a 12.75 %
debenture.
"Due to our strained working capital situation
that had developed through the first and into the second quarters
we anticipated a significant slowdown in shipments from our vendors
in the quarter" said Peter Bruijns,
President and CEO. "With the two capital raises, plus the
incremental debt the company has added $2,272,000 of working capital which has enabled
shipments to resume in Q3. With our high current backlog and
improving project margins we anticipate improved performance from
the company through the remainder of 2012."
About BIOREM Inc.
Biorem is a leading clean technology company that designs,
manufactures and distributes a comprehensive line of
high-efficiency air emissions control systems used to eliminate
odors, volatile organic compounds (VOCs), and hazardous air
pollutants (HAPs). With sales and manufacturing offices across the
continent, a dedicated research facility, a worldwide sales
representative network and more than 700 installed systems
worldwide, Biorem offers state-of-the-art technology-based products
and peace of mind for municipalities, industrial companies and
their surrounding communities. Additional information on Biorem is
available on our website at www.biorem.biz.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Forward-Looking Statements
This press release contains forward-looking statements based on
current expectations. These forward-looking statements contain
various risks and uncertainties that could cause actual results to
differ materially from those reflected in the forward-looking
statements. Risks and uncertainties about the Company's business
are more fully discussed in the disclosure materials, financial
statements and MD&A filed with the securities regulatory
authorities in Canada on
www.sedar.com.
Order Bookings and Order Backlog are non-IFRS
measures that the Company uses to evaluate its sales performance.
Order Bookings are those binding contracts that the Company enters
into with a third party for the delivery of our products or
services. As Order Bookings are received, the contract value
(before any associated sales taxes) is included in the Order
Backlog. The Order Backlog is reduced by the revenue that is
recognized on each project and then adjusted for any currency
changes.
SOURCE Biorem Inc.